J Clin Oncol:曲妥珠单抗治疗HER2低表达乳腺癌的疗效和安全性

2020-02-17 不详 MedSci原创

曲妥珠单抗deruxtecan(T-DXd,前身是DS-8201a)是一种新型的人表皮生长因子受体2(HER2)靶向抗体药物偶联物(ADC),具有拓扑异构酶I抑制剂有效载荷。一项剂量递增和扩展I期研究评估了T-DXd在晚期HER2表达/突变实体肿瘤患者中的安全性和活性。本文报道了T-Dxd以推荐剂量用于HER2低水平乳腺癌的扩展患者的结果。本研究招募晚期/转移的HER2低表达的标准治疗难治性的乳腺

曲妥珠单抗deruxtecan(T-DXd,前身是DS-8201a)是一种新型的人表皮生长因子受体2(HER2)靶向抗体药物偶联物(ADC),具有拓扑异构酶I抑制剂有效载荷。一项剂量递增和扩展I期研究评估了T-DXd在晚期HER2表达/突变实体肿瘤患者中的安全性和活性。本文报道了T-Dxd以推荐剂量用于HER2低水平乳腺癌的扩展患者的结果。

本研究招募晚期/转移的HER2低表达的标准治疗难治性的乳腺癌患者。予以5.4或6.4 mg/kg T-Dxd,静滴,1次/3周,直到撤出研究、出现不可耐受的毒性或病程进展。评估抗肿瘤活性和安全性。

2016年8月-2018年8月,共招募了54位患者,至少接受了一剂量的T-Dxd。患者接受了多次预处理(中位既往治疗7.5次)。客观缓解率为37.0%(20/54),缓解中位持续时间为10.4个月。大部分患者(53/54,98.1%)至少发生过1次需紧急治疗的不良反应事件(63%)。最常见的3级及以上的不良反应事件有中性粒细胞减少、血小板减少、WBC计数减少、贫血、低钾血症、AST升高、食欲减退和腹泻。三位以6.4kg/mg剂量治疗的患者发生了与T-Dxd诱导的间质性肺疾病相关的致命性事件。

本研究显示,该新型HER2 靶向ADC,T-Dxd,对于HER2低表达乳腺癌患者具有初始抗肿瘤活性。大部分毒性反应为肠道血液学方面的。间质性肺疾病是一种重要的风险识别,应密切监测并积极管理

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720926, encodeId=b0531e2092678, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Feb 22 21:33:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 02 05:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865787, encodeId=d9451865e8772, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 15 06:33:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032408, encodeId=f38510324085c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037987, encodeId=8d70103e98796, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720926, encodeId=b0531e2092678, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Feb 22 21:33:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 02 05:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865787, encodeId=d9451865e8772, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 15 06:33:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032408, encodeId=f38510324085c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037987, encodeId=8d70103e98796, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720926, encodeId=b0531e2092678, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Feb 22 21:33:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 02 05:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865787, encodeId=d9451865e8772, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 15 06:33:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032408, encodeId=f38510324085c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037987, encodeId=8d70103e98796, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-05-15 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720926, encodeId=b0531e2092678, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Feb 22 21:33:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 02 05:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865787, encodeId=d9451865e8772, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 15 06:33:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032408, encodeId=f38510324085c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037987, encodeId=8d70103e98796, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-02-17 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1720926, encodeId=b0531e2092678, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Feb 22 21:33:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648158, encodeId=76501648158d2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 02 05:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865787, encodeId=d9451865e8772, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 15 06:33:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032408, encodeId=f38510324085c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037987, encodeId=8d70103e98796, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Feb 17 16:33:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-02-17 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

HER2阳性早期乳腺癌更佳辅助治疗方案

HER2阳性乳腺癌是重要的浸润性乳腺癌亚型,也是精准医疗应用于乳腺癌的最成功范例之一。目前,曲妥珠单抗辅助治疗是HER2阳性早期乳腺癌的标准疗法。多项研究探索了辅助抗HER2治疗的最优化方案。在2019年ESMO大会上,来自德国慕尼黑大学乳腺癌中心Nadia Harbeck教授带来了“HER2阳性早期乳腺癌最佳辅助治疗方案”的主题演讲,以下为您带来主要观点。

病例:曲妥“方舟”,HER2阳性乳腺癌的“新”希望

HER2阳性乳腺癌是一种侵袭性强、复发率高、预后不良的乳腺癌类型。临床实践中,HER2阳性乳腺癌患者在肿瘤较大,又有保乳意愿时需要考虑新辅助治疗。新辅助治疗能够缩短手术时间,减少术后并发症,甚至部分患者能够增加保乳、保腋窝的机会。本文分享一例HER2阳性乳腺癌患者通过新辅助治疗获益的病例,分享这类患者的诊疗思路。

NEJM:Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

研究认为,在曲妥珠单抗和卡培他滨治疗基础上,添加Tucatinib可显著提高HER 2阳性转移性乳腺癌患者的无进展生存期和总体生存期

J Clin Oncol:ERCC1表达水平对上消化道肿瘤化疗疗效的影响

以铂类为基础的化疗是治疗HER2阴性的晚期胃食管癌(AEGC)的标准治疗方案。回顾性资料表明,瘤内ERCC1水平或可决定对铂类的敏感性。Iqbal等人开展了一项随机化的II期试验,评估AEGC患者采用以铂类位基础的化疗联合氟尿嘧啶、甲酰四氢叶酸和奥沙利铂(FOLFOX) 对比无铂类的包含伊立替康和多西他赛(IT)治疗的疗效是否因ERCC1水平的不同而有所不同。招募 了202位未治疗过的HER2阴性

王碧芸:2019年HER2+乳腺癌进展盘点

进展1 CLEOPATRA研究 CLEOPATRA研究是一项Ⅲ期、随机、双盲、安慰剂对照研究,入组808例HER2阳性晚期转移性乳腺癌(MBC)患者,旨在比较一线曲妥珠单抗联合化疗基础上,增加帕妥珠单抗是否能够进一步改善HER2阳性晚期乳腺癌患者的预后,以及三药联合治疗的安全性。 该研究首次证明在曲妥珠单抗联合化疗基础上增加帕妥珠单抗能够改善HER2阳性晚期乳腺癌的无进展生存和总生存

NEJM:曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

研究认为,曲妥珠单抗Deruxtecan在先前治疗失败的HER2阳性转移性乳腺癌患者中显示出持久的抗肿瘤活性